Relmada Therapeutics (RLMD) Liabilities and Shareholders Equity (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $235.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 750.32% year-over-year to $235.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $365.4 million (up 82.45% YoY) and the FY2025 annual result came in at $94.0 million, up 105.17% from the prior year.
• Liabilities and Shareholders Equity rose to $235.4 million in Q1 2026 per RLMD's latest filing, from $94.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $235.4 million in Q1 2026 and bottomed at $14.9 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $97.6 million (2023), against an average of $111.5 million.
• The widest annual swing landed in 2025, when Liabilities and Shareholders Equity slumped 73.3%; it then jumped 750.32% in 2026.
• Tracing RLMD's Liabilities and Shareholders Equity over 5 years: stood at $152.9 million in 2022, then plunged by 36.2% to $97.6 million in 2023, then sank by 53.03% to $45.8 million in 2024, then surged by 105.17% to $94.0 million in 2025, then surged by 150.38% to $235.4 million in 2026.
• Per Business Quant, the three latest RLMD Liabilities and Shareholders Equity figures stand at $235.4 million (Q1 2026), $94.0 million (Q4 2025), and $14.9 million (Q3 2025).

Peer Comparison